Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy.
J Autism Dev Disord
; 2023 May 04.
Article
em En
| MEDLINE
| ID: mdl-37142904
ABSTRACT
We examine the cost-effectiveness of treating epilepsy with anti-epileptic medicines in autistic children, looking at impacts on healthcare providers (in England, Ireland, Italy and Spain) and children's families (in Ireland). We find carbamazepine to be the most cost-effective drug to try first in children with newly diagnosed focal seizures. For England and Spain, oxcarbazepine is the most cost-effective treatment when taken as additional treatment for those children whose response to monotherapy is suboptimal. In Ireland and Italy, gabapentin is the most cost-effective option. Our additional scenario analysis presents the aggregate cost to families with autistic children who are being treated for epilepsy this cost is considerably higher than healthcare provider expenditure.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Health_economic_evaluation
Idioma:
En
Revista:
J Autism Dev Disord
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Reino Unido